TPTX » Topics » Lead M1 Agonist for Cognitive Disorders

This excerpt taken from the TPTX 8-K filed Sep 28, 2006.

Lead M1 Agonist for Cognitive Disorders

Safe and well tolerated in two Phase I studies

Total of 24 healthy adult males, average age 35

Total of 20 healthy elderly, average age 73

Biomarker evidence of selective stimulation of M1 receptor in man
as measured by increased salivation

Achieve blood levels in man comparable to those described in
transgenic mouse study, published in
Neuron, showing NGX267
lowered levels of brain Aß
42

Data also support development as treatment for cognitive
impairment associated with schizophrenia

NGX292, follow-on M1 agonist, is desmethyl derivative of NGX267

20


This excerpt taken from the TPTX DEFA14A filed Sep 28, 2006.

Lead M1 Agonist for Cognitive Disorders

Safe and well tolerated in two Phase I studies

Total of 24 healthy adult males, average age 35

Total of 20 healthy elderly, average age 73

Biomarker evidence of selective stimulation of M1 receptor in man
as measured by increased salivation

Achieve blood levels in man comparable to those described in
transgenic mouse study, published in
Neuron, showing NGX267
lowered levels of brain Aß
42

Data also support development as treatment for cognitive
impairment associated with schizophrenia

NGX292, follow-on M1 agonist, is desmethyl derivative of NGX267

20


This excerpt taken from the TPTX 8-K filed Sep 6, 2006.

Lead M1 Agonist for Cognitive Disorders

Safe and well tolerated in two Phase I studies

Total of 24 healthy adult males, average age 35

Total of 20 healthy elderly, average age 73

Biomarker evidence of selective stimulation of M1 receptor in man
as measured by increased salivation

Achieve blood levels in man comparable to those described in
transgenic mouse study, published in
Neuron, showing NGX267
lowered levels of brain Aß
42

Data also support development as treatment for cognitive
impairment associated with schizophrenia

NGX292, follow-on M1 agonist, is desmethyl derivative of NGX267

18

 

This excerpt taken from the TPTX DEFA14A filed Sep 6, 2006.

Lead M1 Agonist for Cognitive Disorders

Safe and well tolerated in two Phase I studies

Total of 24 healthy adult males, average age 35

Total of 20 healthy elderly, average age 73

Biomarker evidence of selective stimulation of M1 receptor in man
as measured by increased salivation

Achieve blood levels in man comparable to those described in
transgenic mouse study, published in
Neuron, showing NGX267
lowered levels of brain Aß
42

Data also support development as treatment for cognitive
impairment associated with schizophrenia

NGX292, follow-on M1 agonist, is desmethyl derivative of NGX267

18

 

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki